Posted by Michael Wonder on 25 Jan 2022
SNIPR BIOME announces US FDA grants fast track designation for SNIPR001 for prevention of bloodstream infections in haematologic cancer patients
25 January 2022 - SNIPR Biome has been granted fast track designation by the US FDA for SNIPR001.
SNIPR001 is the company’s first development candidate targeting E. coli in patients with haematological malignancy at risk of neutropenia.
